Aldeyra Therapeutics (ALDX) Common Equity (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Common Equity came in at $42.2 million in Q1 2026, down 33.71% YoY from $63.6 million in Q1 2025, and down 4.73% on a QoQ basis from $44.3 million in Q4 2025.
Aldeyra Therapeutics (ALDX) Common Equity (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 14 years of Common Equity data on file, last reported at $42.2 million in Q1 2026.
- Quarterly Common Equity fell 33.71% year-over-year to $42.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.2 million (down 33.71% YoY) and the FY2025 annual result came in at $44.3 million, down 37.68% from the prior year.
- Common Equity declined to $42.2 million in Q1 2026, from $44.3 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $190.7 million in Q1 2022 to a low of $42.2 million in Q1 2026.
- A 5-year average of $106.5 million and a median of $113.4 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity surged 51.25% — and 2025, when it tumbled 43.93%.
- Tracing ALDX's Common Equity over 5 years: stood at $151.0 million in 2022, then slipped by 20.67% to $119.8 million in 2023, then slumped by 40.73% to $71.0 million in 2024, then sank by 37.68% to $44.3 million in 2025, then retreated by 4.73% to $42.2 million in 2026.
- The last three Common Equity figures came in at $42.2 million (Q1 2026), $44.3 million (Q4 2025), and $49.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Aldeyra Therapeutics | 90.18 Mn | 90.18 Mn | - | 37.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.89 Mn |
| Mar 31, 2026 | 42.16 Mn |
| Dec 31, 2025 | 44.25 Mn |
| Sep 30, 2025 | 49.24 Mn |
| Jun 30, 2025 | 55.29 Mn |
| Mar 31, 2025 | 63.60 Mn |
| Dec 31, 2024 | 71.00 Mn |
| Sep 30, 2024 | 85.10 Mn |
| Jun 30, 2024 | 98.31 Mn |
| Mar 31, 2024 | 113.42 Mn |
| Dec 31, 2023 | 119.80 Mn |
| Sep 30, 2023 | 123.01 Mn |
| Jun 30, 2023 | 129.88 Mn |
| Mar 31, 2023 | 137.24 Mn |
| Dec 31, 2022 | 151.01 Mn |
| Sep 30, 2022 | 162.19 Mn |
| Jun 30, 2022 | 174.03 Mn |
| Mar 31, 2022 | 190.69 Mn |
| Dec 31, 2021 | 205.74 Mn |
| Sep 30, 2021 | 219.67 Mn |